Stock listing

Savara, Inc.

Selected listing: A2DQ2B · LS · EUR · DE

Savara, Inc. (Lang & Schwarz: A2DQ2B), Health Technology. Latest release Aug 25, 2026: Savara Announces Encore Presentations of Results from the Phase 3…

A2DQ2B:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2DQ2B
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Savara, Inc.

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP)

August 25, 2026

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

July 30, 2026

Savara Announces Chief Financial and Administrative Officer Transition

June 8, 2026

All Savara, Inc. news →

Research Savara, Inc.

Savara, Inc. company profile

View the public company page for Savara, Inc. on 6ix.

Savara, Inc. news

Read company news and market updates connected to Savara, Inc..

Savara, Inc. investor events

Find investor webinars, events, and replay context for Savara, Inc..